Acrivon Therapeutics, Inc.

ACRV · NASDAQ

Acrivon has an AP3-guided oncology platform, a lead ACR-368 endometrial-cancer catalyst, and cash runway into Q3 2027, but it is still pre-revenue and dependent on clinical data, diagnostics, and future financing.

Follow Add to Watchlist Ask Question

NASDAQ ACRV Coverage Bootstrap Health Care Biotechnology Precision Oncology

Latest ReportMay 13, 2026Acrivon Therapeutics: the cancer-data story with a 2026 readout clockView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Company filters1 of 1 reports match

Clear filters

Add tags

Selected tags

Precision OncologyNasdaq

Clear tags

MatchAny tag All tags

Latest Thesis

Acrivon Therapeutics: the cancer-data story with a 2026 readout clock

May 13, 2026Research reportSlides available

Read report Open slides Discussion (0)

Acrivon Therapeutics, Inc.Therapeutics: the cancer-data story with a 2026 readout clockMay 13, 2026

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Recent Reports

Compact report index for this company.

View all 1 reports ->

ReportTypeUpdatedReadActions

Acrivon Therapeutics: the cancer-data story with a 2026 readout clockAcrivon has an AP3-guided oncology platform, a lead ACR-368 endometrial-cancer catalyst, and cash runway into Q3 2027, but it is still pre-revenue and dependent on clinical data, diagnostics, and future financing.NASDAQMay 13, 2026Research reportRead Slides